Precision Measurement of 11Li moments: Influence of Halo Neutrons on the 9Li Core

The electric quadrupole moment and the magnetic moment of the 11Li halo nucleus have been measured with more than an order of magnitude higher precision than before, |Q| = 33.3(5)mb and mu=3.6712(3)mu_N, revealing a 8.8(1.5)% increase of the quadrupole moment relative to that of 9Li. This result is compared to various models that aim at describing the halo properties. In the shell model an increased quadrupole moment points to a significant occupation of the 1d orbits, whereas in a simple halo picture this can be explained by relating the quadrupole moments of the proton distribution to the charge radii. Advanced models so far fail to reproduce simultaneously the trends observed in the radii and quadrupole moments of the lithium isotopes.Comment: 4 pages, 4 figures, 1 tabl

Magnetic Moment of the Fragmentation Aligned 61Fe(9/2)+ Isomer

We report on the g factor measurement of the isomer in $^{61}Fe$ ($E^{*}=861 keV$). The isomer was produced and spin-aligned via a projectile-fragmentation reaction at intermediate energy, the Time Dependent Perturbed Angular Distribution (TDPAD) method being used for the measurement of the g factor. For the first time, due to significant improvements of the experimental technique, an appreciable residual alignment of the isomer has been observed, allowing a precise determination of its g factor: $g=-0.229(2)$. Comparison of the experimental g factor with shell-model and mean field calculations confirms the $9/2^+$ spin and parity assignments and suggests the onset of deformation due to the intrusion of Nilsson orbitals emerging from the $\nu g_{9/2}$.Comment: 4 figures. Submitted to Phys. Rev. Let

Precision measurement of the electric quadrupole moment of 31Al and determination of the effective proton charge in the sd-shell

he electric quadrupole coupling constant of the 31Al ground state is measured to be nu_Q = |eQV_{zz}/h| = 2196(21)kHz using two different beta-NMR (Nuclear Magnetic Resonance) techniques. For the first time, a direct comparison is made between the continuous rf technique and the adiabatic fast passage method. The obtained coupling constants of both methods are in excellent agreement with each other and a precise value for the quadrupole moment of 31Al has been deduced: |Q(31Al)| = 134.0(16) mb. Comparison of this value with large-scale shell-model calculations in the sd and sdpf valence spaces suggests that the 31Al ground state is dominated by normal sd-shell configurations with a possible small contribution of intruder states. The obtained value for |Q(31Al)| and a compilation of measured quadrupole moments of odd-Z even-N isotopes in comparison with shell-model calculations shows that the proton effective charge e_p=1.1 e provides a much better description of the nuclear properties in the sd-shell than the adopted value e_p=1.3 e

Study of 19^{19} Na at SPIRAL

NESTERInternational audienceThe excitation function for the elastic-scattering reaction p18Ne, p18Ne was measured with the first radioactive beam from the SPIRAL facility at the GANIL laboratory and with a solid cryogenic hydrogen target. Several broad resonances have been observed, corresponding to new excited states in the unbound nucleus 19Na. In addition, two-proton emission events have been identified and are discussed

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

peer reviewedBackground: The phase IIIb, randomized, parallel-group, placebo-controlled ANDHI double-blind (DB) study extended understanding of the efficacy of benralizumab for patients with severe eosinophilic asthma. Patients from ANDHI DB could join the 56-week ANDHI in Practice (IP) single-arm, open-label extension substudy. Objective: Assess potential for standard-of-care background medication reductions while maintaining asthma control with benralizumab. Methods: Following ANDHI DB completion, eligible adults were enrolled in ANDHI IP. After an 8-week run-in with benralizumab, there were 5 visits to potentially reduce background asthma medications for patients achieving and maintaining protocol-defined asthma control with benralizumab. Main outcome measures for non–oral corticosteroid (OCS)-dependent patients were the proportions with at least 1 background medication reduction (ie, lower inhaled corticosteroid dose, background medication discontinuation) and the number of adapted Global Initiative for Asthma (GINA) step reductions at end of treatment (EOT). Main outcomes for OCS-dependent patients were reductions in daily OCS dosage and proportion achieving OCS dosage of 5 mg or lower at EOT. Results: For non–OCS-dependent patients, 53.3% (n = 208 of 390) achieved at least 1 background medication reduction, increasing to 72.6% (n = 130 of 179) for patients who maintained protocol-defined asthma control at EOT. A total of 41.9% (n = 163 of 389) achieved at least 1 adapted GINA step reduction, increasing to 61.8% (n = 110 of 178) for patients with protocol-defined EOT asthma control. At ANDHI IP baseline, OCS dosages were 5 mg or lower for 40.4% (n = 40 of 99) of OCS-dependent patients. Of OCS-dependent patients, 50.5% (n = 50 of 99) eliminated OCS and 74.7% (n = 74 of 99) achieved dosages of 5 mg or lower at EOT. Conclusions: These findings demonstrate benralizumab's ability to improve asthma control, thereby allowing background medication reduction. © 202